Immune parameters affecting the efficacy of chemotherapeutic regimens - PubMed (original) (raw)
Review
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al. Nat Rev Clin Oncol. 2011 Mar.
Abstract
The outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or alternatively, by increasing their susceptibility to immune attack. In addition, chemotherapy can stimulate anticancer immune effectors either in a direct fashion or by subverting immunosuppressive mechanisms. Beyond cancer-cell-intrinsic factors that determine the cytotoxic or cytostatic response, as well as the potential immunogenicity of tumor cells, the functional state of the host immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies. In this Review, we surmise that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.
Similar articles
- Immune-mediated mechanisms influencing the efficacy of anticancer therapies.
Coffelt SB, de Visser KE. Coffelt SB, et al. Trends Immunol. 2015 Apr;36(4):198-216. doi: 10.1016/j.it.2015.02.006. Trends Immunol. 2015. PMID: 25857662 Review. - Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Zitvogel L, et al. Immunity. 2013 Jul 25;39(1):74-88. doi: 10.1016/j.immuni.2013.06.014. Immunity. 2013. PMID: 23890065 Review. - Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Galluzzi L, et al. Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012. Cancer Cell. 2015. PMID: 26678337 Review. - Contribution of the immune system to the chemotherapeutic response.
McDonnell AM, Nowak AK, Lake RA. McDonnell AM, et al. Semin Immunopathol. 2011 Jul;33(4):353-67. doi: 10.1007/s00281-011-0246-z. Epub 2011 Jan 28. Semin Immunopathol. 2011. PMID: 21274535 Review. - ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.
Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV. Shurin MR, et al. Curr Med Chem. 2012;19(12):1792-803. doi: 10.2174/092986712800099785. Curr Med Chem. 2012. PMID: 22414087 Review.
Cited by
- Immune-modulative nano-gel-nano system for patient-favorable cancer therapy.
Kim SH, Han RT, Han HS, Kim YM. Kim SH, et al. Bioact Mater. 2024 Sep 17;43:67-81. doi: 10.1016/j.bioactmat.2024.08.047. eCollection 2025 Jan. Bioact Mater. 2024. PMID: 39328776 Free PMC article. - Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence.
Zhou D, Li M, Wu W, Wu Y, Nong Q, Wang S, Hong R. Zhou D, et al. Cancer Immunol Immunother. 2024 Sep 5;73(11):223. doi: 10.1007/s00262-024-03783-6. Cancer Immunol Immunother. 2024. PMID: 39235656 Free PMC article. - SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.
Hu J, Li X, Wang Y, Xu B, He P, Wang Z, He L, Chen H. Hu J, et al. Front Immunol. 2024 Jul 12;15:1410284. doi: 10.3389/fimmu.2024.1410284. eCollection 2024. Front Immunol. 2024. PMID: 39072331 Free PMC article. - The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges.
Zhou Z, Huang S, Fan F, Xu Y, Moore C, Li S, Han C. Zhou Z, et al. Med Rev (2021). 2024 Apr 15;4(3):173-191. doi: 10.1515/mr-2023-0061. eCollection 2024 Jun. Med Rev (2021). 2024. PMID: 38919400 Free PMC article. Review. - Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer-Relation to Tumour Characteristics and Impact on Prognosis.
Stout A, Facey N, Bhatnagar A, Rice K, Berditchevski F, Kearns D, Metcalf A, Elghobashy A, Shaaban AM. Stout A, et al. Int J Mol Sci. 2024 Apr 20;25(8):4524. doi: 10.3390/ijms25084524. Int J Mol Sci. 2024. PMID: 38674108 Free PMC article.
References
- Clin Cancer Res. 2007 Mar 1;13(5):1493-502 - PubMed
- Br J Cancer. 2009 Apr 7;100(7):1061-7 - PubMed
- J Clin Oncol. 2005 Oct 10;23(29):7265-77 - PubMed
- Gastroenterology. 2010 Apr;138(4):1429-40 - PubMed
- Adv Immunol. 2006;90:1-50 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources